compound 4d (Egyptian Atomic Energy Authority)

Compound 4d is a novel small molecule thiazoloquinoxaline derivative containing a sulfapyridine moiety, developed by researchers at the Egyptian Atomic Energy Authority as a targeted therapy for hepatocellular carcinoma (HCC). It functions as a potent inhibitor of Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2), a critical receptor involved in tumor angiogenesis and progression. In preclinical studies, compound 4d demonstrated significant cytocidal activity against HepG2 liver cancer cells and effectively suppressed hepatic VEGF expression in vivo. A key advantage of this compound is its improved safety profile compared to the standard-of-care multi-kinase inhibitor sorafenib; it exhibits significantly lower cardiotoxicity, as evidenced by its reduced impact on myocardium cells and the maintenance of normal cardiac enzyme functions in animal models.

Other names

sulfapyridine derivative 4dthiazoloquinoxaline derivative 4d